REG - Angle PLC - Result of open offer

AngleAnnouncement

21/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240621:nRSU3674Ta&default-theme=true

RNS Number : 3674T  Angle PLC  21 June 2024

 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
 INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN
 OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH
 RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

 FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN
 OFFER OF SECURITIES IN ANY JURISDICTION.

 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.
     21 June 2024

 

ANGLE plc (the "Company")

 

Results of Open Offer

 

ANGLE plc (AIM:AGL), a world-leading liquid biopsy company with innovative
circulating tumour cell (CTC) solutions for use in research, drug development
and clinical oncology, is pleased to announce that, pursuant to the Open Offer
announced on 5 June 2024, it has received valid applications for a total of
3,561,121 Open Offer Shares from Qualifying Shareholders.

 

The Open Offer raised gross proceeds of £0.5m at the Issue Price, which will
be used to strengthen the Company's balance sheet. In aggregate, £9.3m of
gross proceeds have been raised pursuant to the Placing, Subscription and Open
Offer.

 

The Open Offer Shares, when issued, will be fully paid and rank pari passu in
all respects with the existing ordinary shares of the Company.  Application
has been made for the Open Offer Shares to be admitted to trading on AIM.
 Admission and settlement of the Open Offer Shares is expected to take place
at 8.00 a.m. on 24 June 2024.

 

Total voting rights

 

Following Second Admission, the Company will have a total of 322,641,668
ordinary shares in issue. With effect from Second Admission, this figure may
be used by shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or a change
to their interest in the Company, under the Disclosure Guidance and
Transparency Rules of the Financial Conduct Authority.

 

Unless otherwise stated, capitalised terms not otherwise defined in the text
of this announcement have the same meanings ascribed to them as in the Launch
Announcement published by the Company on 5 June 2024.

 

 

For further information:

 

 ANGLE plc                                                     +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD & Corporate Broker)

 Toby Flaux, Ciaran Walsh, Milo Bonser, Brooke Harris-Lowing   +44 (0) 20 3207 7800

 FTI Consulting (Financial PR)

 Simon Conway, Ciara Martin                                    +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                                      +1 (212) 850 5624

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
circulating tumour cell (CTC) harvesting technology known as the Parsortix®
PC1 System enables complete downstream analysis of the sample including whole
cell imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix® system, associated
consumables and assays. The clinical services business is offered through
ANGLE's GCLP-compliant laboratories.  Services include custom made assay
development and clinical trial testing for pharma.

 

Over 90 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit https://angleplc.com/
(https://angleplc.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIFBMATMTATMJI